-transparent.png){kind=logo}
5-Vinylpyrimidine nucleosides can be readily synthesized via organometallic intermediates from commercially available nucleosides. Highly potent and selective inhibitors of herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) are (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and some related analogs such as (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU), 1-beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil (BVaraU) and (E)-5-(2-bromovinyl)-2'-deoxycytidine (BVDC). The selective antiviral action of BVDU is based upon a specific phosphorylation by the virus-encoded deoxythymidine kinase (TK), inhibition of the viral DNA polymerase and/or incorporation into viral DNA. The efficacy of BVDU against HSV-1 and VZV infections has been demonstrated in animal models and phase I clinical trials. Possible limitations in the clinical usefulness of 5-vinylpyrimidine nucleosides in general and BVDU in particular are discussed.
E De Clercq, and
R T Walker
January 2016,
Nucleosides, nucleotides & nucleic acids,
E De Clercq, and
R T Walker
January 1992,
Bioorganicheskaia khimiia,
E De Clercq, and
R T Walker
January 2021,
Chemistry of heterocyclic compounds,
E De Clercq, and
R T Walker
October 2009,
European journal of medicinal chemistry,
E De Clercq, and
R T Walker
June 1976,
Biochemical pharmacology,
E De Clercq, and
R T Walker
May 2004,
Clinics in liver disease,
E De Clercq, and
R T Walker
May 2004,
Mini reviews in medicinal chemistry,
E De Clercq, and
R T Walker
April 1976,
Journal of medicinal chemistry,
E De Clercq, and
R T Walker
September 1994,
Journal of medicinal chemistry,
E De Clercq, and
R T Walker
February 2017,
Tetrahedron letters,
